MDLA Posts Solid Double-Digit Net Income and Gross Profit Gains in H1 2025

PT Medela Potentia Tbk (MDLA), the holding company with operations spanning in the distribution and marketing of pharmaceutical products, healthcare products, medical devices, medical device manufacturing, and digital health platforms, delivered robust operational results in the first half of 2025.

For the six months ended June 30, 2025, MDLA booked net sales of IDR 7.42 trillion, up from IDR 7.15 trillion in the same period last year. Net income rose at a double-digit pace to IDR 200.33 billion, compared to IDR 173.06 billion in H1 2024, reflecting management’s success in enhancing profitability while maintaining operational efficiency.

President Director PT Medela Potentia Tbk Krestijanto Pandji said the results validate the company’s strategic moves to integrate all subsidiary business lines, spanning distribution, marketing, manufacturing, and health service digitalization. “Post-IPO, our focus has been on accelerating sustainable growth while maintaining a healthy capital structure,” he said.

As of June 30, 2025, MDLA’s total assets reached IDR 6.26 trillion, up from IDR 5.73 trillion at year-end 2024. The increase was supported by higher cash and cash equivalents from IPO proceeds and additional working capital to support business expansion.

Total liabilities fell to IDR 3.21 trillion from IDR 3.52 trillion at the end of 2024, reflecting healthier and more efficient financial management as the company strengthened its capital structure and optimized operating cash flows. Total equity jumped to IDR 3.04 trillion from IDR 2.20 trillion, reinforcing MDLA’s solid financial position following the inflow of public funds.

Management reaffirmed its commitment to strengthening MDLA’s position as an integrated player in Indonesia’s healthcare sector, including promoting medical device self-sufficiency through investments in manufacturing capabilities and distribution digitalization. “We are optimistic this positive momentum will continue through year-end,” Krestijanto said.

The company continues to enhance its nationwide logistics and distribution infrastructure as part of its sustainable expansion strategy. A key milestone was securing full ownership, through subsidiary PT Anugrah Argon Medica (AAM), of the National Distribution Center (NDC), which has long served as its primary distribution hub. In Sumatra, MDLA is also boosting its presence with plans to expand capacity at AAM’s Medan branch warehouse to accelerate delivery times and broaden distribution reach.

From a supply chain perspective, MDLA is leveraging technology to optimize processes, most notably implementing artificial intelligence (AI) for demand planning, inventory management, and delivery efficiency to improve forecasting accuracy. This enables the company to anticipate demand trends more precisely, avoiding overstock or shortages that affect working capital efficiency. With predictive algorithms that adapt to market dynamics, MDLA aims to optimize working capital needs without compromising speed or reliability in distribution.

“With digital and AI-driven systems, we are not only improving planning accuracy but also building a more responsive and efficient supply chain to serve an ever-changing market,” said Director of PT Medela Potentia Tbk, Wimala Widjaja.

On the manufacturing side, MDLA relies on subsidiary PT Deca Metric Medica (DMM) as a strategic production arm specializing in internationally certified medical devices. DMM holds ISO 13485:2016 certification from the British Standards Institution (BSI), underscoring its commitment to quality and compliance with global standards. The facility provides MDLA with full control over product quality and flexible production capacity, offering a competitive edge amid rising domestic medical device demand. DMM is preparing for its first export to regional markets.

 “DMM is a testament to our commitment to strengthening Indonesia’s healthcare industry through globally certified manufacturing. In addition to meeting our internal needs, DMM is open to contract manufacturing or OEM collaborations, enabling strategic partners to produce high-quality medical devices in our certified facility,” said Director of PT Medela Potentia Tbk, Edbert Orotodan.

MDLA is also advancing its ESG agenda by converting 50% of its fuel-powered logistics fleet to electric vehicles across 15 branches in 13 cities, totaling 106 units. This initiative has reduced the company’s logistics-related CO₂ emissions by 5%.

 “We continue to build a strong operational foundation to ensure business sustainability and resilience in the long term. Infrastructure development, supply chain efficiency, and enhanced manufacturing capabilities remain our strategic pillars in navigating the evolving industry landscape,” Krestijanto concluded.